NEWS & MEDIA

Neovacs to present kinoid technology and its clinical outlooks at upcoming keystone symposia conference

Paris and Boston, March 9, 2017 – Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that Géraldine Grouard-Vogel, PhD., Chief Scientific Officer of Neovacs, will present an update on the Company’s IFNα Kinoid program in Lupus, Dermatomyositis and Type 1 Diabetes, at the 2017 Keystone Symposia Conference, taking place March 19 – 23, 2017, in Banff, Alberta, Canada.

Download pdf